Gainers

• OPKO Health (NASDAQ:OPK) shares increased by 34.7% to $1.67 during Tuesday's regular session. The company's market cap stands at $936.3 million. As per the press release, Q2 earnings came out yesterday.
• ProMIS Neurosciences (NASDAQ:PMN) stock increased by 25.74% to $14.74. The company's market cap stands at $105.1 million.
• Kiniksa Pharmaceuticals (NASDAQ:KNSA) stock increased by 24.43% to $79.06. The company's market cap stands at $4.8 billion. As per the news, the Q2 earnings report came out today.
• CytoMed Therapeutics (NASDAQ:GDTC) shares increased by 17.8% to $1.06. The market value of their outstanding shares is at $10.6 million.
• Repligen (NASDAQ:RGEN) stock increased by 15.64% to $151.56. The market value of their outstanding shares is at $7.3 billion. As per the press release, Q2 earnings came out today.
• VSee Health (NASDAQ:VSEE) stock moved upwards by 15.0% to $0.09. The company's market cap stands at $3.7 million.

Losers

• Enlivex (NASDAQ:ENLV) shares declined by 43.7% to $2.4 during Tuesday's regular session. The market value of their outstanding shares is at $71.7 million.
• Bristol-Myers Squibb Company Celegne Contingent Value Rights (NYSE:CELGR) stock decreased by 31.11% to $0.08.
• Replimune Group (NASDAQ:REPL) stock decreased by 30.6% to $5.99. The market value of their outstanding shares is at $724.4 million.
• Nautilus Biotechnology (NASDAQ:NAUT) stock fell 28.62% to $1.19. The company's market cap stands at $210.9 million. The company's, Q2 earnings came out today.
• Advanced Biomed (NASDAQ:ADVB) stock declined by 28.1% to $10.32. The company's market cap stands at $23.4 million.
• China SXT Pharmaceuticals (NASDAQ:SXTC) shares fell 25.51% to $0.05. The market value of their outstanding shares is at $2.6 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.